Overview
- Omada Health reported new study findings showing its GLP-1 Care Track helped members achieve greater weight loss and improved body composition compared with a control group.
- Participants in the program lost 1.8 times more weight, reduced body fat twice as much, and increased muscle mass percentage while reporting better physical and mental well-being.
- The findings suggest Omada’s wraparound care model may enhance GLP-1 treatment outcomes by promoting higher-quality weight loss.
The News
Omada Health announced results from a 12-week study involving 245 adults with obesity who had recently initiated GLP-1 therapy for weight management. Participants enrolled in Omada’s GLP-1 Care Track lost an average of 6.0% of their starting weight compared with 3.3% in the control group. They also reduced body fat percentage twice as much (3.3%) and increased muscle mass percentage nearly threefold while reporting improvements in mental health, physical function, and confidence in managing their weight.
The GLP-1 Care Track combines personalized strength training, digital tools, and human coaching to support sustainable weight loss and preserve lean mass—an important concern with GLP-1 therapies. The findings are part of Omada’s ANSWERS Initiative, which evaluates real-world outcomes from its behavior change and weight management programs.
Industry Perspective
As GLP-1 therapies become widely adopted, healthcare providers and employers are increasingly focusing on treatment quality rather than weight loss alone. Programs that combine medication with structured lifestyle interventions are gaining attention for their potential to preserve muscle mass, improve body composition, and enhance long-term health outcomes.
Strategic Impact
The study reinforces Omada’s position in the growing GLP-1 companion care market by demonstrating the value of combining virtual coaching, strength-focused exercise, and digital support with obesity medications. The results could strengthen Omada’s appeal to employers, health plans, and healthcare providers seeking evidence-based programs that maximize the long-term benefits of GLP-1 therapy.
Source: Globenewswire
